Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.

Rosenbloom MH, Brown J, Berlowitz DR, Budson AE. Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2011 Feb 1; 26(2):108-10.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


Abstract:

OBJECTIVE: To demonstrate the safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. DESIGN: One group, pretest-posttest SETTING: Veterans Affairs (VA) hospital serving U.S. veterans. PATIENTS, PARTICIPANTS: Charts of 193 patients changed from donepezil to galantamine SA were reviewed. INTERVENTION: In an effort to limit the cost of medications being used for Alzheimer's disease, the Bedford VA Hospital began an initiative to transition patients to the generic sustained-release galantamine SA. A chart review was performed using the VA computerized patient record for all patients transitioned from either donepezil or rivastigmine to galantamine. Progress notes were reviewed for the first three months following initial medication exchange to determine galantamine tolerability and reasons for discontinuation. MAIN OUTCOME MEASURE: Galantamine SA tolerability at three months. RESULTS: Of the 193 patients transitioned to galantamine SA, 94.3% remained on the drug at three months. The most common reason for medication withdrawal was mental status change (n = 5). CONCLUSION: Transition to galantamine SA in a real world clinical setting was well-tolerated among patients with dementia.




Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.